Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
The incidence and prevalence of inflammatory bowel diseases (IBDs) are rapidly increasing worldwide. IBDs are considered an emerging problem not only in Western countries but also in developing counties. The relapses and complications of active IBD mandate various medications. Nevertheless, hospital...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Association of Internal Medicine
2022-09-01
|
| Series: | The Korean Journal of Internal Medicine |
| Subjects: | |
| Online Access: | http://kjim.org/upload/pdf/kjim-2022-132.pdf |
| _version_ | 1828112450544730112 |
|---|---|
| author | Jihye Park Jae Hee Cheon |
| author_facet | Jihye Park Jae Hee Cheon |
| author_sort | Jihye Park |
| collection | DOAJ |
| description | The incidence and prevalence of inflammatory bowel diseases (IBDs) are rapidly increasing worldwide. IBDs are considered an emerging problem not only in Western countries but also in developing counties. The relapses and complications of active IBD mandate various medications. Nevertheless, hospitalization, emergency room visits, or surgery may be required, resulting in a socioeconomic burden. Great advances have been made in the development of new therapeutic options for IBD to achieve induction and maintenance remission. Nevertheless, conventional therapy is still the mainstay in the treatment of IBD. This review article provides an update on recent advances in conventional therapies, including 5-aminosalicylates, corticosteroids, immunomodulators, and anti-tumor necrosis factor-α agents to treat IBD. |
| first_indexed | 2024-04-11T11:49:25Z |
| format | Article |
| id | doaj.art-06b90a1663b34e9dbb03961ed495223a |
| institution | Directory Open Access Journal |
| issn | 1226-3303 2005-6648 |
| language | English |
| last_indexed | 2024-04-11T11:49:25Z |
| publishDate | 2022-09-01 |
| publisher | The Korean Association of Internal Medicine |
| record_format | Article |
| series | The Korean Journal of Internal Medicine |
| spelling | doaj.art-06b90a1663b34e9dbb03961ed495223a2022-12-22T04:25:25ZengThe Korean Association of Internal MedicineThe Korean Journal of Internal Medicine1226-33032005-66482022-09-0137589590510.3904/kjim.2022.132170711Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-αJihye Park0Jae Hee Cheon1 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea Department of Internal Medicine, Yonsei University College of Medicine, Seoul, KoreaThe incidence and prevalence of inflammatory bowel diseases (IBDs) are rapidly increasing worldwide. IBDs are considered an emerging problem not only in Western countries but also in developing counties. The relapses and complications of active IBD mandate various medications. Nevertheless, hospitalization, emergency room visits, or surgery may be required, resulting in a socioeconomic burden. Great advances have been made in the development of new therapeutic options for IBD to achieve induction and maintenance remission. Nevertheless, conventional therapy is still the mainstay in the treatment of IBD. This review article provides an update on recent advances in conventional therapies, including 5-aminosalicylates, corticosteroids, immunomodulators, and anti-tumor necrosis factor-α agents to treat IBD.http://kjim.org/upload/pdf/kjim-2022-132.pdfinflammatory bowel diseasesmesalamineadrenal cortex hormonesimmunologic factorsanti-tnf agents |
| spellingShingle | Jihye Park Jae Hee Cheon Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α The Korean Journal of Internal Medicine inflammatory bowel diseases mesalamine adrenal cortex hormones immunologic factors anti-tnf agents |
| title | Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α |
| title_full | Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α |
| title_fullStr | Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α |
| title_full_unstemmed | Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α |
| title_short | Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α |
| title_sort | updates on conventional therapies for inflammatory bowel diseases 5 aminosalicylates corticosteroids immunomodulators and anti tnf α |
| topic | inflammatory bowel diseases mesalamine adrenal cortex hormones immunologic factors anti-tnf agents |
| url | http://kjim.org/upload/pdf/kjim-2022-132.pdf |
| work_keys_str_mv | AT jihyepark updatesonconventionaltherapiesforinflammatoryboweldiseases5aminosalicylatescorticosteroidsimmunomodulatorsandantitnfa AT jaeheecheon updatesonconventionaltherapiesforinflammatoryboweldiseases5aminosalicylatescorticosteroidsimmunomodulatorsandantitnfa |